TY - JOUR
T1 - GR89,696
T2 - A potent κ-opioid agonist with subtype selectivity in rhesus monkeys
AU - Butelman, Eduardo R.
AU - Ko, M. C.Holden
AU - Traynor, John R.
AU - Vivian, Jeffrey A.
AU - Kreek, Mary Jeanne
AU - Woods, James H.
PY - 2001
Y1 - 2001
N2 - GR89,696 is a synthetic κ-opioid receptor agonist, recently reported to have an agonist profile consistent with selectivity at the proposed "κ2" subtype. The present studies evaluated the effects of GR89,696 in vitro {i.e., in radioligand binding and [35S]guanosine-5′-O-(3-thio)triphosphate assays} and in vivo in rhesus monkeys, in assays used to study κ-opioid agonists (i.e., thermal antinociception, sedation and muscle relaxation, diuresis, and increases in serum prolactin levels, as well as ethylketocyclazocine and U69,593 discrimination). Furthermore, the sensitivity of GR89,696 to naltrexone and nor-binaltorphimine (nor-BNI) antagonism was compared with that of U50,488 and U69,593, ligands selective for the proposed "κ1" subtype. Overall, GR89,696 displayed the profile of a highly potent κ-opioid agonist, following parenteral administration in rhesus monkeys. GR89,696 was less sensitive than U50,488 and U69,593 to naltrexone or nor-BNI antagonism, consistent with an action through the proposed κ2 receptor subtype.
AB - GR89,696 is a synthetic κ-opioid receptor agonist, recently reported to have an agonist profile consistent with selectivity at the proposed "κ2" subtype. The present studies evaluated the effects of GR89,696 in vitro {i.e., in radioligand binding and [35S]guanosine-5′-O-(3-thio)triphosphate assays} and in vivo in rhesus monkeys, in assays used to study κ-opioid agonists (i.e., thermal antinociception, sedation and muscle relaxation, diuresis, and increases in serum prolactin levels, as well as ethylketocyclazocine and U69,593 discrimination). Furthermore, the sensitivity of GR89,696 to naltrexone and nor-binaltorphimine (nor-BNI) antagonism was compared with that of U50,488 and U69,593, ligands selective for the proposed "κ1" subtype. Overall, GR89,696 displayed the profile of a highly potent κ-opioid agonist, following parenteral administration in rhesus monkeys. GR89,696 was less sensitive than U50,488 and U69,593 to naltrexone or nor-BNI antagonism, consistent with an action through the proposed κ2 receptor subtype.
UR - http://www.scopus.com/inward/record.url?scp=0034883666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034883666&partnerID=8YFLogxK
M3 - Article
C2 - 11504802
AN - SCOPUS:0034883666
SN - 0022-3565
VL - 298
SP - 1049
EP - 1059
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 3
ER -